By the time she was 17, Alexandra Newton had lived in seven different countries and had mastered four different languages. But her family was not surprised when she chose to pursue a career in biochemistry instead of language arts.
Rudy Tanzi, Ph.D., chair of the Cure Alzheimer's Fund Research Consortium, was named one of TIME Magazine's '100 Most Influential People of 2015' in a list published earlier this week.
Tanzi has long been known for his pioneering work in Alzheimer's disease research, especially Alzheimer's genetics. He made an especially important contribution to the field in 2014 with his lab's "Alzheimer's in a Dish" breakthrough, a tool that will be used to enhance our understanding of the disease and accelerate drug discovery.
For the fourth year in a row, Cure Alzheimer’s Fund has received a 4-star rating – the highest possible – from watchdog organization Charity Navigator. Charity Navigator rates over 8,000 nonprofits on many aspects of their accountability, transparency and fiscal responsibility.
As reported recently in the New York Times (Business Day, March 20, 2015, “Biogen Reports Its Alzheimer’s Drug Sharply Slows Cognitive Decline”) and other media, the pharmaceutical company Biogen has announced impressive results in a Phase I “human safety” trial of a new drug designed to treat — and possibly prevent — Alzheimer’s disease.
In a recent news piece, Massachusetts General Hospital (MGH) chose to highlight Cure Alzheimer's Fund's support of research through the lab of Dr. Rudy Tanzi.
MGH praises the venture capital approach taken by CAF co-founders Jeff and Jacqui Morby, enabling researchers like Tanzi to take risks and pursue "paradigm changing" studies. And the risks have paid off: According to MGH, the scientific results brought about by CAF-funded research are "nothing short of game changing, as Mass General researchers resolve some long-unanswered questions about how Alzheimer’s disease develops."
Released today, the President's Fiscal Year 2016 Budget includes several important increases for medical research. The National Institutes of Health (NIH) will receive an additional $1 billion, incuding $68 million for the National Institute on Aging. These represent roughly a 1.1% and a 3.3% increase in NIH and NIA's respective budgets.
Building on its enormously successful “Whole Genome Sequencing” Project, which identified nearly 1,000 new genetic mutations in more than 50 different genes, Cure Alzheimer's Fund has announced a new, even more ambitious multiyear, $50 million plus program titled “Genes to Therapies” (G2T). Simply put, the new project’s goal is to use the most promising recent genetic discoveries to develop drugs that would stop the disease at three separate stages:
Cure Alzheimer's Fund Chairman and Co-Founder Jeff Morby and Co-Founder Jacqui Morby were featured for their support of Alzheimer's research in Sunday's Pittsburgh Post-Gazette. The article highlights Cure Alzheimer's Fund's success and the commitment of its founders and board to cover all operating costs. The Post-Gazette also describes the origins of the fund, which started off under the Pittsburgh Foundation until the Morbys garnered enough support to launch a public charity.
New research by David Holtzman, M.D. at the Washington University School of Medicine points to a sleep regulation protein in the brain as a possible target for Alzheimer's disease treatment or prevention. The protein, called orexin, plays a role in rousing the brain from sleep.